Xeris Biopharma SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 5, 2026, 7:12 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedXeris Biopharma Q3 2026 diluted EPS $0.06 beats $0.027 consensus; revenue $107.2 million tops $101.7 million; full-year revenue guidance raised to $395-$405 million
8-KNov. 2, 2026, 8:05 a.m. ETView on SEC.gov
Departure/appointment of directors or officers · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedXeris Biopharma Appoints Menassie Taddese to Board of Directors and Audit Committee
8-KOct. 14, 2026, 7:08 a.m. ETView on SEC.gov
Other events
AI summary, unreviewedXeris Biopharma Files Patent Infringement Suits Against Generic Keveyis (dichlorphenamide) Makers Following '502 Patent Grant
8-KSept. 9, 2026, 8:33 a.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits
8-KAug. 6, 2026, 7:12 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits